(2025) demonstrated HBO as a potential therapy when reporting that HBOT-treated GBM cells had significantly decreased expression of HIF-1α and HIF-2α when compared to the control group, allowing for chemosensitization (164). This evidence concerns the gene HIF1A and glioblastoma.